Tags : Mycapssa

Chiasma Reports Results of Mycapssa (octreotide) in P-III CHIASMA OPTIMAL

Tuba Khan July 23, 2019

Shots: The P-III CHIASMA OPTIMAL study involves assessing of Mycapssa formulated as capsules vs PBO in 56 patients in a ratio (1:1) with acromegaly prior treated with somatostatin analogs for […]readmore

Tags : Mycapssa

Chiasma Reports Results of Mycapssa (octreotide) in P-III CHIASMA OPTIMAL

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Mycapssa

Chiasma Reports Results of Mycapssa (octreotide) in P-III CHIASMA OPTIMAL

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company